No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects.
OBJECTIVE
To examine the effect of a GLP-2 infusion on appetite sensations and ad libitum energy intake in healthy, normal weight humans.


METHODS
The experiment was performed in a randomised, blinded, and placebo-controlled crossover design. Placebo or GLP-2 was infused (infusion rate of 25 pmol/kg body wth) for 4.5 h.


METHODS
A total of 18 healthy, normal weight young subjects participated; eight women and 10 men.


METHODS
During the infusion, subjects recorded their appetite sensations every 30 min using visual analogue scales, and blood was sampled frequently. After 2 h of infusion, an ad libitum meal, consisting of sandwiches, was served.


RESULTS
The concentration of GLP-2 was significantly higher during the GLP-2 infusion compared with placebo (P<0.0001) and increased further in both conditions in response to the meal. Neither appetite sensations, nor palatability of the test meals, or energy intake were different on the two occasions. Glucose, GLP-1, insulin, and GIP responses were also unaffected by the infusion, whereas glucagon levels were higher during the GLP-2 treatment (P<0.05).


CONCLUSIONS
Circulating GLP-2 in physiological concentrations does not seem to play a significant role in human appetite regulation.
Sørensen
L B
LB
Department of Human Nutrition, Centre for Advanced Food Studies, The Royal Veterinary and Agricultural University, Frederiksberg C, Denmark. lbs@kvl.dk
Flint
A
A
Raben
A
A
Hartmann
B
B
Holst
J J
JJ
Astrup
A
A
D000328:Adult; D001066:Appetite / Q000502:physiology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D002149:Energy Intake / Q000502:physiology*; D005247:Feeding Behavior; D005260:Female; D052216:Glucagon-Like Peptide 1; D053767:Glucagon-Like Peptide 2; D006801:Humans; D008297:Male; D010455:Peptides / Q000097:blood*; D019518:Postprandial Period; D012527:Satiation
D053767:Glucagon-Like Peptide 2; D010455:Peptides; D052216:Glucagon-Like Peptide 1